How Successful Are AI-Discovered Drugs in Clinical Trials? A First Analysis and Emerging Lessons

There is reason to believe that AI techniques could further improve clinical performance, especially in Phase II and III trials. Understanding the drivers of disease and identifying and validating drug targets is an area where many AI-native biotechs, pharmaceutical companies, and academic institutions are actively investing. In this paper, the authors' findings show that benefits are beginning to manifest in clinical trials. They believe the results of their analysis paint an intriguing picture for the future of R&D. In the coming years, as more clinical results for AI-discovered molecules become available, it will be exciting to see how AI techniques will impact R&D productivity overall.